Nyxoah (NASDAQ:NYXH) PT Lowered to $19.00 at Stifel Nicolaus

Nyxoah (NASDAQ:NYXH) had its target price trimmed by Stifel Nicolaus from $27.00 to $19.00 in a research report report published on Monday morning, Benzinga reports. The firm currently has a buy rating on the stock.

Several other analysts also recently weighed in on the company. Piper Sandler upped their price objective on Nyxoah from $15.00 to $20.00 and gave the stock an overweight rating in a research report on Wednesday, March 6th. Oppenheimer dropped their price objective on Nyxoah from $20.00 to $15.00 and set an outperform rating for the company in a research report on Wednesday, May 15th. HC Wainwright dropped their price objective on Nyxoah from $22.00 to $18.00 and set a buy rating for the company in a research report on Friday, May 24th. Finally, Cantor Fitzgerald lowered their target price on Nyxoah from $18.00 to $17.00 and set an overweight rating for the company in a report on Wednesday, May 15th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of Moderate Buy and a consensus target price of $17.80.

Nyxoah Price Performance

NASDAQ:NYXH opened at $6.87 on Monday. The stock has a fifty day moving average price of $9.24 and a 200-day moving average price of $9.83. The company has a current ratio of 3.94, a quick ratio of 3.70 and a debt-to-equity ratio of 0.13. Nyxoah has a fifty-two week low of $4.00 and a fifty-two week high of $20.00.

Nyxoah (NASDAQ:NYXH) last announced its quarterly earnings data on Tuesday, May 14th. The company reported ($0.45) earnings per share for the quarter, hitting the consensus estimate of ($0.45). Nyxoah had a negative return on equity of 42.14% and a negative net margin of 843.49%. The business had revenue of $1.33 million during the quarter, compared to the consensus estimate of $1.20 million. As a group, research analysts forecast that Nyxoah will post -1.72 earnings per share for the current year.

Institutional Investors Weigh In On Nyxoah

An institutional investor recently bought a new position in Nyxoah stock. Ikarian Capital LLC purchased a new stake in Nyxoah S.A. (NASDAQ:NYXH) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 50,699 shares of the company’s stock, valued at approximately $684,000.

Nyxoah Company Profile

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.